Kronos Bio Inc. (KRON) IPO Opens 50% Higher

Today's IPO for Kronos Bio Inc. (NASDAQ: KRON) opened for trading at $28.5 after pricing 13,157,895 shares of its common stock at a price to the public of $19.00 per share.

In addition, Kronos Bio has granted the underwriters a 30-day option to purchase up to an additional 1,973,684 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

Goldman Sachs & Co. LLC, Jefferies, Cowen and Piper Sandler are acting as joint book-running managers for the offering.

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. The company has headquarters in San Mateo, Calif., and a research facility in Cambridge, Mass.

You May Also Be Interested In

• Scribe Therapeutics files for proposed Nasdaq IPO
• Viking Acquisition Corp. II prices $200M IPO on NYSE
• Osprey Acquisition Corp. III raises $300M in Nasdaq IPO